Mianserin is a tetracyclic antidepressant belonging to the piperazinoazepine class of compounds. It acts primarily by modulating central monoaminergic neurotransmission and is classified pharmacologically as a noradrenergic and specific serotonergic antidepressant (NaSSA)-related compound.
Mianserin has been used in the treatment of depressive disorders and is also associated with sedative and anxiolytic effects. It is a specialized CNS pharmaceutical API used in pharmaceutical development and research.
Mianserin API is a specialized antidepressant pharmaceutical ingredient used in the development and manufacture of CNS formulations.
For the product page, it is important to distinguish Mianserin free base from Mianserin Hydrochloride. Mianserin free base has CAS 24219-97-4, while Mianserin Hydrochloride has CAS 21535-47-7.
Product: Mianserin
CAS Number: 24219-97-4
Molecular Formula: C18H20N2
Molecular Weight: 264.36 g/mol
Hydrochloride CAS: 21535-47-7
Hydrochloride Formula: C18H21ClN2
Hydrochloride Molecular Weight: 300.80 g/mol
Drug Class: Tetracyclic Antidepressant
Therapeutic Class: Antidepressant
Therapeutic Area: Psychiatry / CNS
Molecule Type: Synthetic Small Molecule
Mianserin acts on several central neurotransmitter systems. Its pharmacological profile includes antagonism at central α2-adrenergic receptors and activity at several serotonin receptors.
The resulting pharmacological effects include:
Mianserin API is associated with:
The current BP description identifies Mianserin Hydrochloride as a monoamine reuptake inhibitor and tetracyclic antidepressant.
Mianserin Hydrochloride has been used in oral pharmaceutical formulations, particularly tablets.
Mianserin free base is a crystalline solid. For the hydrochloride form, the British Pharmacopoeia monograph specifies the substance as Mianserin Hydrochloride with CAS 21535-47-7 and molecular mass 300.8.
A controlled Mianserin API manufacturing process may involve:
For Mianserin Hydrochloride, the BP/Ph. Eur. monograph includes testing for:
The published BP 2025 monograph specifies pH 4.0–5.5, loss on drying NMT 0.5%, and sulfated ash NMT 0.1%.
Mianserin Hydrochloride should be protected from light according to the BP monograph.
Mianserin is relevant to research involving:
| Parameter | Specification |
|---|---|
| Appearance | White crystalline powder or crystals |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 0.5% |
| Residue on Ignition | NMT 0.5% |
| pH (1% Solution) | 4.0 – 5.5 |
| Individual Impurity | NMT 0.5% |
| Total Impurities | NMT 1.0% |
| Water Content | NMT 0.5% |